DNA Vaccines (Hepatitis)

IL-2 Adjuvant Increases HBV DNA Vaccine Efficacy

Published in Vaccine Weekly, March 10th, 1997

The use of DNA vaccines in combination with interleukin-2 adjuvant may provide a simple approach to overcoming nonresponsiveness to hepatitis B surface antigen vaccines and vaccines for other diseases, according to a report from Taiwan.

Researcher Yen-Hung Chow and colleagues found that the coexpression of interleukin 2 (IL-2) dramatically increased the efficacy of hepatitis B virus (HBV) DNA vaccines.

Immunization with vaccines containing HBV surface antigen (HBsAg), prepared from plasma or by genetic engineering, has been effective in preventing the establishment of chronic HBV infections, but approximately 14 percent of vaccinees remain only...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry